<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20134">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02844790</url>
  </required_header>
  <id_info>
    <org_study_id>NN5401-1984</org_study_id>
    <secondary_id>U1111-1173-7678</secondary_id>
    <nct_id>NCT02844790</nct_id>
  </id_info>
  <brief_title>A Trial Investigating the Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart in Healthy Chinese Subjects</brief_title>
  <official_title>A Trial Investigating the Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Asia. The aim of this trial is to investigate the pharmacokinetic
      (the exposure of the trial drug in the body) properties of insulin degludec/insulin aspart
      in healthy Chinese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the serum insulin degludec concentration-time curve</measure>
    <time_frame>From 0 to 120 hours after single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum insulin aspart concentration-time curve</measure>
    <time_frame>From 0 to 12 hours after single dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum insulin degludec concentration</measure>
    <time_frame>After single dose (within 0 to 120 hours after dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum insulin aspart concentration</measure>
    <time_frame>After single dose (within 0 to 12 hours after dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed serum insulin degludec concentration</measure>
    <time_frame>After single dose (within 0 to 120 hours after dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed serum insulin aspart concentration</measure>
    <time_frame>After single dose (within 0 to 12 hours after dosing)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>IDegAsp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin degludec/insulin aspart</intervention_name>
    <description>A single dose of IDegAsp will be administered subcutaneously (s.c., under the skin).</description>
    <arm_group_label>IDegAsp</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female Chinese subject aged 18-45 years (both inclusive)

          -  Considered generally healthy upon completion of medical history, physical
             examination, vital signs and electrocardiogram (ECG), as judged by the investigator

          -  Body mass index 19.0-24.0 kg/m^2 (both inclusive)

        Exclusion Criteria:

          -  A history of any illness that, in the opinion of the investigator, might confound the
             results of the trial or pose risk in administering the trial product to the subject

          -  Subject who has donated any blood or plasma in the past month or more than 400 mL
             within 3 months prior to screening

          -  Smoking more than 5 cigarettes (including nicotine substitute products), or the
             equivalent, per
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 2, 2017</lastchanged_date>
  <firstreceived_date>July 22, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
